Skip to main content
Premium Trial:

Request an Annual Quote

Roche ALK Test Gains FDA Approval as CDx for Zykadia

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Roche's Ventana ALK (D5F3) CDx to identify best responders to Novartis' non-small cell lung cancer drug Zykadia (ceritinib).

The immunohistochemistry test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements, including patients whose cancer has spread to the brain. The assay is available for use on BenchMark IHC/ISH instruments, and is also indicated to identify best responders to Pfizer's ALK inhibitor, Xalkori (crizotinib).

"With the FDA's approval of the expanded use of the Ventana ALK (D5F3) CDx Assay to determine which lung cancer patients are eligible for Zykadia, we are helping clinicians and their patients identify additional treatment options for non-small cell lung cancer," Ann Costello, head of Roche Tissue Diagnostics, said in a statement. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.